Business Context and Reporting Period
This Form 6-K filing by Sanofi (NYSE: SNY) covers the month of June 2012. The report incorporates a press release dated June 1, 2012, announcing positive top-line results from the TOWER Phase III clinical trial for teriflunomide (AUBAGIO), an investigational oral therapy for relapsing forms of multiple sclerosis (MS) developed by Sanofi's subsidiary, Genzyme.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is a regulatory report focused exclusively on clinical trial results and does not contain a financial statement or earnings summary.
Material Changes and Clinical Results
The primary material update concerns the TOWER trial, a double-blind, multi-center study enrolling 1,169 patients. Key results for the proposed 14 mg commercial dose compared to placebo include:
- Annualized Relapse Rate: A statistically significant 36.3% reduction (p<0.0001).
- Disability Progression: A 31.5% reduction in the risk of 12-week sustained accumulation of disability (p=0.0442).
- 7 mg Dose Results: A 22.3% reduction in annualized relapse rate was observed (p=0.02), but no statistically significant difference was found for disability progression.
Adverse events were consistent with previous trials, with the most common being headache, ALT elevations, hair thinning, diarrhea, nausea, and neutropenia. There were four deaths reported during the trial: one in the placebo arm (respiratory infection) and three in the teriflunomide arms (motor vehicle accident, suicide, and sepsis).
Outlook, Risks, and Management Commentary
Management, including Genzyme President and CEO David Meeker, M.D., characterized the results as encouraging and consistent with prior TEMSO study data, highlighting the potential of teriflunomide as a new treatment for relapsing MS. Marketing applications are currently under review by the U.S. FDA, the European Medicines Agency (EMA), and other authorities.
The filing includes standard forward-looking statement disclaimers, noting risks such as:
- Uncertainties inherent in research and development and future clinical data analysis.
- Regulatory decisions regarding approval, labeling, and commercial potential.
- No guarantee of commercial success even if approved.
- Competition from future therapeutic alternatives.
Investor Verification Checklist
- Verify the status of marketing applications with the FDA and EMA for teriflunomide.
- Monitor the presentation of full TOWER data analysis at the forthcoming scientific meeting.
- Review the safety profile details, specifically regarding ALT elevations and neutropenia, in the full clinical study report.
- Assess the competitive landscape for oral MS therapies and potential pricing strategies.
- Confirm the timeline for potential commercial launch and revenue recognition.